Clinical trialNCT02712723Active, not recruitingPhase 2Interventional

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

SponsorQamar KhanEnrollment121Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine if ribociclib in combination with letrozole for 24 weeks as neoadjuvant endocrine therapy increases the proportion of women with Pre-operative Endocrine Prognostic Index (PEPI) score of 0 at surgery compared to patients treated with letrozole alone therefore allowing more patients excellent outcomes without chemotherapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Qamar Khan, MD
University of Kansas Medical Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
City of Hope National Medical Center
Duarte, California, United States
Cancer Research Collaboration
Santa Ana, California, United States
University of Miami Sylvester Comprehensive Cancer Center
Deerfield Beach, Florida, United States
University of Kansas Cancer Center - West
Kansas City, Kansas, United States
University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, United States
University of Kansas Cancer Center - Westwood
Westwood, Kansas, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Kansas Cancer Center - North
Kansas City, Missouri, United States
University of Kansas Cancer Center - South
Kansas City, Missouri, United States
University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
Columbia University Medical Center
New York, New York, United States
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Letrozole →PlaceboRibociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Feb 2016
Primary completion: 27 Aug 2018
Completion: 31 Dec 2026
Last update posted: 11 Mar 2026
Registered enrollment: 121
Registry id: NCT02712723

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.